GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for PARFAIT

PARFAIT

Official Title

BMS-986141 (PAR-4 Antagonist) for Ischemic stroke and TIA

Status

Ongoing

Overview

To evaluate the efficacy and safety of BMS-986141 (PAR-4 Antagonist) for the prevention of recurrent brain infarction in subjects receiving acetylsalicylic acid (ASA) following acute ischemic stroke or transient ischemic attack

Study Design

A phase 2, placebo controlled, randomized, double-blind, parallel-arm trial

Primary Endpoint

Composite of symptomatic ischemic stroke by Day 28 and unrecognized brain infarction assessed by MRI at Day 28.

Number of Patients

1312

Number of Sites

200

Number of Countries

15

Study Period

2016-2019

Principal Investigator

Mike Sharma

Program Manager

Jackie Bosch

Research Coordinator

Jodi Miller

Collaborators

Bristol-Myers Squibb